Articles

WellPoint, peers focus on health reform rules, campaign

WellPoint Inc., UnitedHealth Group Inc. and three other health insurers, criticized by Democrats during the health care reform
debate, are seeking to influence how the new law will be implemented, and possibly change it, by campaigning for supportive
congressional candidates.

Read More

WellPoint gains confidence as profits rise

The Indianapolis-based health insurer raised its full-year profit forecast after it earned $722.4 million, 4 percent higher
than during the same quarter a year ago. Revenue and health plan membership fell.

Read More

Exchanges sprout around the country

When the Indiana Health Information Exchange launched in 2004, it was one of nine truly operational exchanges around the country.
Today, the Indianapolis-based organization is one of 73, according to the latest national survey by the eHealth Initiative.

Read More

Medicare driving health care hookups

The scramble by local hospitals to form their physicians and facilities into “clinically integrated” networks
that can do business with employers and health insurers has another huge motivating factor: Beginning January 2012, they can
also do business with Medicare, the massive federal program for seniors.

Read More

Indiana Medicaid chief: Feds leave states in dark

Indiana and other states face a struggle as they grapple with putting the health care changes into place in a relatively short
span of time while they also contend with the economic downtown and strained state budgets.

Read More

Lilly reveals plans to cut 340 IT jobs

The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.

Read More

Hilbert mansion to be auctioned

CNO Financial Group Inc. will resort to a sealed-bid auction to unload the lavish Hilbert mansion in Carmel, which has been
on the market for five years. Its latest asking price was $9.9 million.

Read More

Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses

Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.

Read More

Lilly to cut 170 manufacturing jobs by year’s end

Eli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.

Read More